Latest research on Atomoxetine

Atomoxetine is the first non-stimulant drug approved for the treatment of attention-deficit hyperactivity disorder (ADHD). It is sold in the form of the hydrochloride salt of atomoxetine. This chemical is manufactured and marketed under the brand name Strattera; by Eli Lilly and Company and as a generic Attentin by Torrent Pharmaceuticals. There is currently no generic available within the United States due to patent restrictions. [Wikipedia]

Atomoxetine and alcohol

We contacted the manufacturers who recommended that stimulants and Atomoxetine not be coingested with alcohol or illicit substances. [source, 2015]
We used the key search terms alcohol, substance related disorders, death, and combined these with Methylphenidate, Atomoxetine, dexamphetamine and Lisdexamfetamine in turn. [source, 2015]
We included articles which mentioned the coingestion of ADHD medication (Methylphenidate, dexamphetamine, Lisdexamfetamine and Atomoxetine) with another substance including alcohol, publications relating to animal models, and, due to the paucity of data regarding adolescents, all age groups. [source, 2015]
Two studies explored combinations of Atomoxetine and alcohol [17, 21]. [source, 2015]
On the basis of experimental studies, and studies of alcohol dependent individuals, when Methylphenidate, dexamphetamine or Atomoxetine are ingested orally with alcohol, acute severe side-effects appear uncommon. [source, 2015]
The following exclusion criteria were used in the study: (1) any current Axis I or Axis II psychiatric disorder (this selection criterion was used to exclude other major psychiatric conditions in the study group so as to avoid potential issues with applicability of the study: to ensure this a semistandardized interview, the Mini International Neuropsychiatric Interview (MINI) compatible with DSM-IV diagnostic criteria [35] was performed on all potential subjects); (2) history of intolerability, hypersensitivity or allergy to Atomoxetine, or use of Atomoxetine within 30 days of screening; (3) presence of disorders that could conceivable be exacerbated by Atomoxetine (specifically, narrow angle closure glaucoma, urinary outflow obstruction, hypertension, and neurological disorders, particularly tics and Tourette's syndrome, or a history of epilepsy or seizures); (4) use of concomitant medication that could potentially interact with Atomoxetine including monoamine oxidase inhibitors (MAOI), antihypertensive medication, or any concomitant medication that was a cytochrome 2D6 inhibitor (CYP2D6), since Atomoxetine's elimination involves the CYP2D6 system; (5) use of any recreational or illegal drugs in the 3 months prior to the study, of individuals who met criteria for alcohol dependence or alcohol abuse in the 3 months prior to the study; (6) presence of any suicidal ideations during screening testing. [source, 2012]
Children were excluded if they (1) were involved in intensive (i.e., weekly) individual or group psychotherapy during the experiment, (2) used medication other than psycho-stimulants or Atomoxetine, (3) had a comorbid disorder, other than oppositional defiant disorder (ODD) or an anxiety disorder, (4) had a neurological disorder and/or a cardiovascular disease, (5) participated in another clinical trial, (5) received neurofeedback training in the past, or (5) used alcohol or drugs. [source, 2010]